Stryker Corp (SYK)
A medical technology company in orthopaedics products. Its products include implants, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation.
Recs
Geriatric pick.
Recs
Low relative PE, good star ranking, PEG & 09 PE still below normal - bottom fishing 10/19.
Recs
Downthumb. Excellent cash flow and payout. 10% sales growth rate but is slowing. 72% margins.
Recs
Note to self & the voting machine:
Give me a $90 per share for this, and I am happy to sell.
Recs
As a "young" baby boomer, I have lived through the bubble of people moving through the system:
- Class sizes of 35-40 in the 1970's
- Competition for jobs when we graduated from college
- Huge need for medical care, especially "spare" parts - knees, hips, shoulders
Stryker is in a great sector - medical. In addition, as other "great" companies are reducing dividends, they have increased their dividend. Statistically, companies paying - and increasing - dividends have performed better over that last 40 years. Individually, I bet on Stryker.
Recs
Baby Boomer body parts - a growth company with dividends
Recs
Big cap orthopedic/medical surgery company that got hammered in the downturn. A tremendous value if you can buy closer to $40. As people turn 60 those hips and knees get squeeky. Demographic trends highly favor the orthopedic business, even as margins decline due to pricing pressure. They will make it up on volume! The stock has performed will historically due to management's never ending focus on financial results.
Recs
This is certainly one of the toughest years for SYK; as with most other med device companies. Yet with their balance sheet, their commitment to their customers and patients, and their high ethical standards, they have used this down year to look internally and vastly improve their compliance and quality processes.
The FDA has been targeting medical device companies recently and Stryker has been investing heavily in both compliance and quality improvements. In the meantime, newly built manufacturing facilities have opened in multiple European countries as well as in China this year. I would say that though the sales and hospital investments on large capital purchases have slowed, Stryker has capitalized on this "down time" to put their cash to work to strengthen their internal processes. Once through this learning curve, they'll be a stronger, more adaptable, and more focused company as the global economies begin to recover. And they'll be out in the front of the pack, fundamentally stronger than before.
Recs
SYK is in the perfect spot to share in the profits of a aging population. The market has turned against the company, after years of out performane. The luster will return.
Keeneman
Recs
No one come close to the market share that SYK has in their medical specialization. (Knees, hips, etc..)
Recs
No debt. Plenty of cash. Steady growth.
Recs
top of class!
Recs
S&P High Growth Rate Dividend Achiever and MF Caps 4 star rating in a growth industry (Medical Instruments and supplies). One of "3 Ridiculously Cheap, High-Quality Companies" ( August 17, 2009). P/E<15, ROE>15, Debt/Equity<0.5
Recs
All the fundamentals and none of the love. They have cash and product, but no one seems to care.
Recs
Trust me on this one
Recs
THINK HEALTH CARE CONTROVERSY WILL HURT IT.
Also will be price pressure on med device.
I am thinking of selling mine.
Recs
Long Term and now is time to get somewhat defensive with picks I think given the rally...but either way it is long term and living longer is hard to put a price on.
Recs
This leader in orthopedic manufacturing is poised for strong growth for years to come as the boomers need new knees and hips, more and more. Betting on the boomers to age is about as sure a bet as you can find...
Recs
Joint replacement and medical supplies. The future is full of old people
Recs
They have been around for many years, so they have a solid base to their company with limited competitors. They are also coming out with new products to help the spine, which really hasnt been explored by other companies yet.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 195 1 2 3 4 5 6 7 8 9 10 Next »